Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK105 plus anlotinib for persistent, recurrent, or metastatic cervical cancer
ChiCTR2100053109Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Mar 2022
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of penpulimab and anlotinib, sponsored by The First Affiliated Hospital of Zhengzhou University. Started Mar 2022; status: recruiting.
02
Drugs
penpulimabanlotinib
Beyond the preview
Go deeper on ChiCTR2100053109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053109.